Corey Davis, Ph.D. | Relationship Manager
Corey Davis has 22 years of experience as a sell-side equity research analyst covering a diverse array of biotech and specialty pharmaceutical companies. He joins most recently from Seaport Global Securities, and has previously been Managing Directors at Canaccord Genuity, Jefferies, HC Wainwright, Natixis Bleichroeder, and J.P. Morgan (and its predecessor Hambrecht & Quist). His therapeutic expertise spans the gamut from ophthalmology, dermatology, gastroenterology, endocrinology, urology, and oncology to anti-infectives, pulmonary, cardiovascular, pain, and all of the CNS disorders (depression, anxiety, schizophrenia, ADHD, multiple sclerosis, Parkinson’s, epilepsy, insomnia, narcolepsy, migraine, etc.). He has also worked with many different Orphan Disease-related companies. He has formally covered well over 200 names throughout the course of his career with a special focus on small and mid-cap companies. He is particularly adept at advising on topics such as earnings models and projections, guidance philosophies, valuation approaches, clinical trial design, optimizing data disclosure events, non-deal roadshows, and hosting R&D days. He has won numerous awards including multiple Institutional Investor rankings, and The Wall Street Journal’s “Best on the Street”. He graduated magna cum laude from Middlebury College in 1991 and received his Ph.D. in molecular biology from Princeton University in 1997.